Ovid Therapeutics Inc. 8-KCurrent Reports (8-K / ad hoc)

Market for Equity / Stockholders

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Executive Transition On July 5, 2026, Ovid Therapeutics Inc. (the “Company”) and Jeffrey Rona, who served as the Company’s Chief Business and Financial Officer, principal financial officer, principal accounting officer and secretary, mutually agreed to Mr. Rona’s transition from such roles with the Company, effective July 6, 2026 (the “Separation Date”). In connection with Mr. Rona’s departure, the Company’s Board of Directors (the “Board”) appointed Charles Carter, the Company’s Senior Vice President of Finance and Financial Planning, as the Company’s Chief Financial Officer, principal financial officer, principal accounting officer and secretary, effective as of the Separation Date. Mr. Rona’s departure was not the result of any disagreement with the Company on any matter relating to the Company’s accounting practices, financial statements, internal controls over financial reporting, operations, policies or practices. Mr. Carter, age 59, served as the Company’s Senior Vice President of Finance and Financial Planning from October 2024 to July 2026. From February 2024 to September 2024, he was the Chief Financial Officer and Corporate Secretary of CERo Therapeutics Holdings, Inc. (Nasdaq: CERO), a cellular immunotherapy company (“CERo”), during which time he prepared the company for a complex de-SPAC transaction and helped launch CERo as a public company. Prior to that, Mr. Carter was Senior Director at Danforth Advisors, LLC, a strategic consulting firm for life sciences companies (from June 2022 to February 2024), during which time he headed the finance and accounting functions for multiple biotech companies. Previously, Mr. Carter held Chief Financial Officer roles at the following medical device companies: iCAD, Inc. (Nasdaq: ICAD) (from May 2021 to May 2022) and GI Dynamics, Inc. (ASX: GID) (from December 2018 to May 2021). Mr. Carter holds a BS in biology and chemistry from Colgate University and an MBA and a MS in molecular genetics from The University of Chicago. Mr. Carter’s Compensation Arrangements In connection with Mr. Carter’s appointment, Mr. Carter will receive an annual base salary of $460,000 and be eligible for an annual cash bonus with a target amount equal to 35% of his annual base s